English | 简体中文 | 繁體中文 | 한국어 | 日本語
Thursday, 1 August 2019, 11:41 JST
Share:
    

Source: Eisai
Eisai to Refresh and Launch Sahne Cream After 20 Years with Mild Scent and New Package

TOKYO, Aug 1, 2019 - (JCN Newswire) - Eisai Co., Ltd. announced today that it refresh its SAHNE CREAM (quasi-drug) which has been widely used as medical skin care, for the first time in 20 years, and launch at pharmacies and drug stores in Japan on today August 1, 2019.


SAHNE brand marks its 65th anniversary this year. Since the initial launch, SAHNE CREAM has been close to the lifestyle of women who have changed with the times. Eisai is aiming for a brand used by generations around 30's, and will respond to the today's woman needs of easy and simple care at anytime and anywhere such as at home, office, and outside by this refresh of SAHNE CREAM.

The brand name SAHNE is originated from the German word for "cream", and is named under the image of fluffy and smooth of whipped cream. SAHNE CREAM, which has been particular about skin absorbing cream, is quickly absorbing and not sticky, and can be quickly applied on hands, fingers, and whole body care such as neck, decollete, elbows, knees, and heels during housework, childcare, and work as daily care of bare skin.

Compared to the existing products, new SAHNE CREAM has refreshed with mild scent, and the design has changed based on English logo SAHNE and red, which it blends in with the everyday life of mature women while maintaining the moisture and smooth comfort ability.

Eisai is striving to deliver a rich daily life to a wider range of customers through SAHNE CREAM, and to contribute for further improvement of benefits with products and services that meet diverse needs with staying close to customers' lives.

Contact:
Media Inquiries:
Public Relations Department,
Eisai Co., Ltd.
+81-(0)3-3817-5120


Topic: Press release summary
Source: Eisai

Sectors: Healthcare & Pharm
https://www.acnnewswire.com
From the Asia Corporate News Network


Copyright © 2026 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.

 

Eisai Related News
Friday, 27 March 2026, 20:14 JST
Application Submitted for LENVIMA(R) (lenvatinib) in Japan Seeking Approval of Additional Dosage and Administration for Combination with WELIREG(R) (belzutifan) for Renal Cell Carcinoma that has Progressed After Chemotherapy
Friday, 27 March 2026, 18:19 JST
Eisai and Nuvation Bio Announce Marketing Authorisation Application for Taletrectinib for the Treatment of Advanced ROS1-Positive Non-Small Cell Lung Cancer Validated by the European Medicines Agency
Monday, 23 March 2026, 11:19 JST
Results from Real-World, Long-Term Treatment Persistence with LEQEMBI(R) (lecanemab-irmb) in the United States Presented at AD/PD(TM) 2026
Thursday, 19 March 2026, 10:54 JST
Eisai: Regarding Discontinuation of Administration of "Tazverik(R) Tablets 200mg" (tazemetostat hydrobromide)
Tuesday, 17 March 2026, 19:49 JST
Eisai Established the Global Capability Centre in Visakhapatnam, India, to Standardize Global IT Infrastructure Operations and Digital Transformation
More news >>
Copyright © 2026 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Cookies Policy | Privacy Policy | Disclaimer | Terms of Use | RSS
US: +1 214 890 4418 | China: +86 181 2376 3721 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575